Plan B “Not Approvable” Decision Puts FDA, CDER Director In Hot Seat
Executive Summary
FDA's "not approvable" decision for Barr Labs' emergency contraceptive Plan B over-the-counter switch puts the agency back in the spotlight of presidential campaign politics
You may also be interested in...
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
Plan B Delay Draws Criticism From Congress, Academia, FDA Official
FDA's handling of Barr's application to switch Plan B over the counter could elicit heightened external scrutiny of the agency's ability to make drug approval decisions based solely on science and public health